Premium
Alterations of retinal vessel size after single injection of intravitreal anti‐VEGF for diabetic macular edema
Author(s) -
Akpolat C.,
Kurt M.,
Cekic O.
Publication year - 2016
Publication title -
acta ophthalmologica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.534
H-Index - 87
eISSN - 1755-3768
pISSN - 1755-375X
DOI - 10.1111/j.1755-3768.2016.0401
Subject(s) - medicine , ranibizumab , ophthalmology , retinal , fundus (uterus) , central retinal artery , bevacizumab , central retinal vein , edema , fluorescein angiography , surgery , chemotherapy
Purpose To determine the affect of single injection of intravitreal anti‐vascular endothelial growth factor on the retinal vessel caliber in eyes with diabetic macular edema. Methods Overall 32 patients were enrolled in ranibizumab group, 30 patients were included in bevacizumab group. Each of these groups also was divided into two others consisting of study group and control group. The study groups were composed of injected eyes while the non‐injected fellow eyes served as control group. The patients underwent complete ophthalmic examinations including optical coherence tomography and fundus fluorescein angiography. The primary outcome measures were central retinal artery equivalent (CRAE), central retinal vein equivalent (CRVE) and artery‐to‐vein ratio (AVR). Results In ranibizumab study group ( n = 32), pre‐injection mean CRAE (175.42 μ m) decreased to 169.01 μ m at one week and to 167.47 μ m at one month (p < 0.001) while baseline CRVE (235.29 μ m) decreased initially to 219.90 μ m at one week then to 218.36 μ m at one month (p < 0.001). In bevacizumab study group ( n = 30), pre‐injection CRAE (150.21 μ m) decreased to 146.25 μ m at one week and to 145.89 μ m at one month (p < 0.001) while baseline CRVE (211.87 μ m) decreased initially to 204.59 μ m at one week then to 205.24 μ m at one month (p < 0.001). Pre‐injection AVR values changed significantly (p = 0.001) at one week and at one month in ranibizumab group, but no significant alteration of AVR was observed in bevacizumab group (p = 0.433). In the control groups of both ranibizumab ( n = 32) and bevacizumab ( n = 30), none of the three parameters altered throughout the study period compared to the baseline (p > 0.05). Conclusions Both ranibizumab and bevacizumab injection significantly constricted retinal vessel diameters in eyes with diabetic macular edema.